Perceptive Advisors’s Cullinan Therapeutics CGEM Stock Holding History
Bought
Maintained
Sold
Other funds holding CGEM
LCM
KCM
SL
Perceptive Advisors's CGEM Position: Q2 2026 in Review
Perceptive Advisors opened a new position in Cullinan Therapeutics (CGEM) in Q2 2026: 426,478 shares worth $7.77M. The stake represents 0.12% of the portfolio and ranks #86 among its holdings. This is a return to the name: Perceptive Advisors previously reported a position in CGEM as recently as Q1 2025.
Perceptive Advisors first reported a position in CGEM in Q2 2024 and has held it in 3 quarters since. The position peaked at $13.1M in Q2 2024. 183 funds tracked by Wall St. Rank hold CGEM as of Q2 2026.
- Perceptive Advisors held 426,478 shares of Cullinan Therapeutics worth $7.77M as of Q2 2026.
- Cullinan Therapeutics was a new Perceptive Advisors position in Q2 2026.
- Cullinan Therapeutics made up 0.12% of Perceptive Advisors's portfolio in Q2 2026, its #86 holding.
- Perceptive Advisors first reported a position in Cullinan Therapeutics in Q2 2024 and has held it in 3 quarters since.
- Perceptive Advisors's Cullinan Therapeutics position peaked at $13.1M in Q2 2024.
- 183 funds tracked by Wall St. Rank held Cullinan Therapeutics as of Q2 2026.
Based on Perceptive Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.